Keywords: hycamtin, approved, sclc, smithkline, beecham, topoisomerase, inhibitor

Hycamtin Approved For SCLC

Article | 14 September 1998

SmithKline Beecham's topoisomerase I inhibitor Hycamtin (topotecan) hasbeen approved in Switzerland for the second-line treatment of small cell lung cancer. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Hycamtin

Topotecan Hydrochloride

Go to drug listing